The Gut Microbiome Is a Pharmacological Organ — And We're Accidentally Destroying It With Every Antibiotic Course

Your gut microbiome metabolizes drugs. Not as a side effect — as a primary pharmacological pathway. The microbiome modifies >150 drugs including cardiac glycosides (digoxin), anti-cancer agents (irinotecan), and immunomodulators. Zimmermann et al. (2019, Nature) showed that 2/3 of tested drugs are significantly metabolized by gut bacteria.

This means drug efficacy and toxicity depend on your microbiome composition. The same dose of the same drug produces wildly different outcomes in patients with different microbiomes. And every course of antibiotics reshuffles this metabolic organ.

Hypothesis: Microbiome-adjusted pharmacology — dosing drugs based on a patient's gut metagenomic profile — will improve drug efficacy by >30% and reduce adverse events by >40% for microbiome-sensitive drugs.

The mechanism: a patient's microbiome is sequenced before prescribing. Metabolic modeling predicts how their specific bacterial community will modify the drug. Dose and formulation are adjusted accordingly.

Currently, we treat the microbiome as noise. It's signal.

Testable prediction: A pharmacomicrobiomics-guided dosing protocol for irinotecan (a chemotherapy agent with well-characterized microbial metabolism) will reduce severe diarrhea (grade 3-4) by >50% compared to standard dosing, in a 200-patient RCT.

DeSci can build the open-source pharmacomicrobiomics database. Every patient who sequences their microbiome and reports drug responses contributes to a dataset no single pharma company would build.

Your gut is a drug factory. Time we started reading its manual.